News

Public · Published

Alembic Pharmaceuticals Q2 Results: Shares jump 20% after profit rises 81%; US business grows 77%

Alembic Pharmaceuticals reported September-quarter revenue of ₹2,603 crore, up 36.3% year on year, and profit after tax of ₹335 crore, up 81.1%. US formulations revenue increased 77% to ₹1,003 crore, and the company launched three products in the US market during the quarter.

Published:

Updated:

What happened

Alembic Pharmaceuticals reported September-quarter revenue of ₹2,603 crore, up 36.3% year on year, and profit after tax of ₹335 crore, up 81.1%. US formulations revenue increased 77% to ₹1,003 crore, and the company launched three products in the US market during the quarter.

Confirmed

Global impact / market context

Higher revenue and profit indicate stronger business performance, while the US segment’s growth provides a substantial contribution to sales. If growth continues, it could support earnings and cash available for investment; however, the article gives no detail on whether these results will persist.

Analyst inference

The reported gains were broad: India branded sales grew 14%, ex-US sales 12%, and active pharmaceutical ingredients sales 39%, while the US led at 77%. EBITDA, a measure of operating earnings before interest, taxes and certain non-cash costs, rose 78.7%; its share of revenue also increased.

Confirmed

What to watch

  1. Whether Alembic sustains US formulations growth after launching three products in the quarter; the article does not say how much those launches contributed to sales. Analyst inference
  2. Whether the company receives further abbreviated new drug application approvals, regulatory clearances to sell generic medicines; it received one this quarter, bringing the total to 245. Analyst inference
  3. Whether revenue and profit growth continue in later quarters, particularly across US and other businesses; the supplied article provides results only for the September quarter. Analyst inference

Evidence

  • Original source link unavailable